Supraclavicular Bupivacaine Vs. Supraclavicular Liposomal Bupivacaine for Orthopedic Wrist Surgery
Randomized Controlled Trial of Supraclavicular Bupivacaine Vs. Supraclavicular Liposomal Bupivacaine for Orthopedic Wrist Surgery
University of North Carolina, Chapel Hill
100 participants
Apr 10, 2024
INTERVENTIONAL
Conditions
Summary
Orthopedic wrist procedures often cause significant postoperative pain. A supraclavicular nerve block is an effective and proven method to help reduce postoperative pain and decrease opioid use around the time of upper extremity surgery. Liposomal bupivacaine (Exparel) has been approved for use around the brachial plexus, but its analgesic efficacy has limited data. The investigators' goal is to evaluate the effectiveness of Exparel as compared to plain bupivacaine. The investigators hope to ensure the quality of pain control around the time of distal radius fracture repair and reduce the variability of care at the investigators institution by prospectively and rigorously collecting perioperative data during this study.
Eligibility
Inclusion Criteria2
- Age greater than or equal to 18
- Scheduled for orthopedic wrist surgery at University of North Carolina at Chapel Hill.
Exclusion Criteria5
- Contraindications to regional anesthesia
- Emergent surgery Open fractures will be treated emergently and will not allow adequate lead time for enrollment in this study. Also, open fractures are usually accompanied by other traumatic injuries that would confound the pain related outcomes in this study.
- Significant peripheral neuropathy or neurological disorder affecting the upper extremity
- Pregnancy Pregnant women have physiologic changes that make them more sensitive to local anesthetics. That would introduce a confounding element in interpreting the effectiveness of the peripheral nerve blocks being studied.
- Cognitive or psychiatric condition that might affect patient assessment and/or inability to provide informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
133mg Liposomal bupivacaine plus 10mL 0.5% bupivacaine administered in a supraclavicular single shot perineural injection
20mL 0.25% bupivacaine administered in a supraclavicular single shot perineural injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06179004